Raptor Pharmaceutical has presented results from a network meta-analysis of data from clinical trials of inhaled tobramycin, colistimethate sodium, aztreonam and levofloxacin for the treatment of P. aeruginosa lung infections in CF patients. The data, which were presented at the 2016 European Respiratory Society International Congress, show the efficacy of its Quinsair levofloxacin inhalation solution is comparable to the others.
The network meta-analysis included 7 studies with at least 4 weeks of follow-up and 9 studies with at least 24 weeks of follow-up, reported in a total of 685 articles.
Raptor Chief Medical Officer Krishna R. Polu commented, “This network meta-analysis suggests that inhaled levofloxacin provides a useful addition to our armory in the fight against this common and difficult to treat infection. Given the chronicity and reduction in survival caused by P. aeruginosa infection in CF, the availability of inhaled levofloxacin is an important option for clinicians to maintain lung function in CF patients and an important step in tackling the unmet need in the CF community.”
Quinsair, formerly called Aeroquin, was approved in the EU in March 2015 and received QIDP status from the FDA earlier this year. Raptor acquired Quinsair from Tripex Pharmaceuticals in 2015.
Read the Raptor Pharmaceutical press release.
